Related Experiment Video
Updated: Oct 20, 2025

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
Published on: February 9, 2021
XIST Inhibition Attenuates Calcium Oxalate Nephrocalcinosis-Induced Renal Inflammation and Oxidative Injury via the
Peng Lv1, Haoran Liu2,3, Tao Ye1
1Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
The roles of the lncRNA X inactive specific transcript (XIST) in many diseases, including cancers and inflammatory sickness, have been previously elucidated. However, renal calculus remained poorly understood. In this study, we revealed the potential effects of XIST on kidney stones that were exerted via inflammatory response and oxidative stress mechanisms. We established a glyoxylate-induced calcium oxalate (CaOx) stone mouse model and exposed HK-2 cells to calcium oxalate monohydrate (COM). The interactions among XIST, miR-223-3p, and NOD-like receptor protein 3 (NLRP3) and their respective effects were determined by RNAs and protein expression, luciferase activity, and immunohistochemistry (IHC) assays. Cell necrosis, reactive oxygen species (ROS) generation, and inflammatory responses were detected after silencing XIST, activating and inhibiting miR-223-3p, and both knocking down XIST and activating miR-223-3p in vitro and in vivo. The XIST, NLRP3, caspase-1, and IL-1β levels were notably increased in kidney samples from glyoxylate-induced CaOx stone model mice. XIST knockdown significantly suppressed the inflammatory damage and ROS production and further attenuated oxalate crystal deposition. miRNA-223-3p mimics also exerted the same effects. Moreover, we verified the interactions among XIST, miRNA-223-3p and NLRP3, and the subsequent effects. Our results suggest that the lncRNA XIST participates in the formation and progression of renal calculus by interacting with miR-223-3p and the NLRP3/Caspase-1/IL-1β pathway to mediate the inflammatory response and ROS production.
Insights
Long non-coding RNA XIST promotes kidney stone formation by increasing inflammation and oxidative stress. XIST interacts with miR-223-3p and NLRP3 pathway, driving renal calculus progression.
Area of Science:
- Molecular Biology
- Nephrology
- Biochemistry
Background:
- Long non-coding RNA XIST (X inactive specific transcript) roles are known in diseases like cancer.
- Its function in renal calculus (kidney stones) is not well understood.
- Kidney stones involve inflammatory and oxidative stress pathways.
Purpose of the Study:
- To investigate the role of XIST in kidney stone formation.
- To elucidate the underlying mechanisms involving inflammation and oxidative stress.
- To explore the interaction between XIST, miR-223-3p, and NLRP3 in renal calculus.
Main Methods:
- Established a glyoxylate-induced calcium oxalate (CaOx) kidney stone mouse model.
- Utilized HK-2 cells exposed to calcium oxalate monohydrate (COM).
- Performed RNA/protein expression, luciferase activity, and IHC assays to determine molecular interactions and effects.
Main Results:
- XIST, NLRP3, caspase-1, and IL-1β levels were elevated in kidney stone models.
- XIST knockdown and miR-223-3p activation reduced inflammation, oxidative stress (ROS), and crystal deposition.
- Confirmed interactions among XIST, miR-223-3p, and NLRP3, impacting the NLRP3/Caspase-1/IL-1β pathway.
Conclusions:
- lncRNA XIST contributes to renal calculus formation and progression.
- XIST mediates inflammatory response and ROS production via the miR-223-3p and NLRP3 pathway.
- Targeting XIST may offer a therapeutic strategy for kidney stones.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
06:32Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions
Published on: June 13, 2025
Related Concept Videos
X-Inactivation
Urinary Tract Calculi III: Medical Management